We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are OK with this.     OK  No, I would like to know more...
Home / About Novasep / Media & Events / Press releases

Press releases

Michel Spagnol appointed President and CEO of Novasep

26 Jun 2013

Pompey, France, 26 June 2013 - Novasep, a leading provider of purificationbased manufacturing solutions for life sciences molecules, today announces the appointment of Michel Spagnol as President and CEO of the company, effective from 25 June 2013. He will succeed Patrick Glaser, who after three years at Novasep in France, has decided to return to the USA. Michel Spagnol joins Novasep from Shasun, where he was President and Chief Technology Officer. He is a proven business leader with core expertise in leading contract manufacturing of active pharmaceutical ingredients and, more broadly, strong experience in using and developing innovative technologies to address needs of customers in fine chemicals and life sciences fields. Prior to Shasun Michel Spagnol spent his career at Rhodia in Lyon and Cranbury (NJ, USA) where he progressed first in technical R&D leadership roles and subsequently transitioned to business development as a Sales and Marketing Vice President of Rhodia Pharma Solutions.

Novasep appoints Udo Steinhauer as fine chemicals market director, strengthening its fine chemical business

04 Jun 2013

Pompey, France and Leverkusen, Germany, June 4, 2013 - Novasep, a leading supplier of manufacturing solutions to the life sciences industry, announces it has strengthened its position in the fine chemicals marketplace with the appointment of Udo Steinhauer as fine chemicals market director within the synthesis business unit of Novasep.

Novasep discovers explosive properties of Togni reagent II

16 Apr 2013

Novasep reclassifies reagent and informs market about new safety measures required.

Novasep sponsors Smart Synthesis & Advanced Purification Conference 22.04.2013 - 23.04.2013, Hilton Hotel Lyon - Lyon

25 Feb 2013

State of the Art Processes in Large Scale Production of Pharmaceuticals and Fine Chemicals.

Novasep launches the Sius(TM) single-use TFF skid, completing the first 100 per cent single-use TFF solution for pre-clinical to clinical cGMP biomanufacturing

14 Feb 2013

Sius(TM) TFF skid to be showcased at the Disposable Solutions for Biomanufacturing tradeshow in Brussels on February 19-20, 2013.

Novasep invests EUR 30 million to build world’s largest chromatography plant for the pharmaceutical industry

10 Oct 2012

New plant on its Mourenx, France site to produce a large volume commercial API.

Changes to Novasep governance Roger-Marc Nicoud becomes Non-Executive Chairman of the Board Patrick Glaser, Head of Novasep Synthesis, is appointed President and CEO - (10/2/2012)

02 Oct 2012

Pompey, France, 2nd October 2012 - Novasep, a leading provider of purification-based manufacturing solutions for life science molecules, today announces the appointment of Roger-Marc Nicoud, founder and CEO, as Non-Executive Chairman of the Board, effective on October 1st, 2012.

Novasep invests 3 million euros to boost its HPAPI manufacturing capabilities - (7/19/2012)

19 Jul 2012

Pompey, France, July 19, 2012 - Novasep, a leading supplier of manufacturing solutions to the life sciences industries, announces today a three million euro investment to expand its Highly Potent API (HPAPI) manufacturing capabilities at its Le Mans (France) facility. The expansion has been designed to allow Novasep to serve the increased demand for manufacturing of novel anti-cancer therapies.

Novasep strengthens its management team with the appointment of Jean-Claude Romain as Corporate Quality Director and Alain Lamproye as Director of Novasep Bioproduction sites in Belgium - (4/23/2012)

23 Apr 2012

Pompey, France, April 23, 2011 – Novasep, a leading supplier of purification and production solutions for the life sciences industry, announces two new managerial appointments. Jean-Claude Romain becomes the group’s Corporate Quality Director and a member of Novasep’s executive committee, while Alain Lamproye joins Novasep Process, the company’s biomolecules division, as Director of Novasep Belgium and becomes a member of Novasep Process’s management committee.

Novasep’s outstanding results in scale-up and biomanufacturing of Apo-A1 acknowledged by Cerenis at BioProcess International Conference - (4/16/2012)

16 Apr 2012

Cerenis Therapeutics to present manufacturing data for this biopharmaceutical against atherosclerotic cardiovascular disease at BioProcess International (BPI) Conference in Prague (Czech Republic), April 18, 2012.

You can stay on this page and select more documents or you can directly download the brochure(s) you selected
Give us your feedback!